Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study
Nature Cancer
Precision Medicine Group joins McKesson's Oncology & Multispecialty segment. Read more in McKesson Business Highlights.
Peer-reviewed articles and conference poster presentations
Research Article
Download Article
Research Article
Download Article
Research Article
Download Poster
Research Article
Download Article
Research Article
Download Research Article
Research Article
Download Research Article
Research Article
Download Research Article
Research Article
Download Research Article